

[incubator alumni]
C2I is very happy for our graduates and we wish them inspiration, success, and new scientific breakthroughs.

Anastasis Bio is a research-stage company founded in 2020 to develop therapeutics inspired by the work of professors Denise Montell of UC Santa Barbara and Shoukat Dedhar of The University of British Columbia. Our research focuses on targeting novel pathways involved in tumor cell survival, proliferation, and metastasis.

A biotechnology company intended to develop human antibodies as therapeutics for infectious disease.


Archimmune is an immuno-oncology platform company. Its first program is aimed at developing standardized antigen capturing nanoparticles that form a personalized, systemically-acting cancer vaccine in situ when injected intra-tumorally following radiotherapy. The second program exploits the ability of nanocarriers to simultaneously and bi-/tri-specifically engage with selected tumor and/or IO targets.




MaxThera's strategy is to limit resistance emergence to combine the use of these new targets in biosynthetic pathways - essential for bacterial survival - with novel structural classes of compounds.

The Martin Trust Center for MIT Entrepreneurship provides the expertise, support, and connections MIT students need to become effective entrepreneurs.